Citadel Advisors’s BioNexus Gene Lab BGLC Stock Holding History

Citadel Advisors’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,877	Closed	-$23.3K	–	12587
2025 Q1	$23.3K	Buy	+9,877	New	+$34.8K	﹤0.01%	13031
2024 Q1	–	Sell	-3,359	Closed	-$18.1K	–	14565
2023 Q4	$18.1K	Sell	3,359 -1,816	-35%	-$10.3K	﹤0.01%	12702
2023 Q3	$43.5K	Buy	+5,175	New	+$84.3K	﹤0.01%	11911

Other funds holding BGLC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BGLC Position: Q2 2025 in Review

Citadel Advisors sold out of BioNexus Gene Lab (BGLC) in Q2 2025, closing a stake of 9,877 shares — an estimated $23.3K sold.

Citadel Advisors first reported a position in BGLC in Q3 2023 and held it in 3 quarters. The position peaked at $43.5K in Q3 2023. 1 fund tracked by Wall St. Rank holds BGLC as of Q2 2025.

Citadel Advisors reported no remaining BioNexus Gene Lab position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 9,877 BioNexus Gene Lab shares in Q2 2025, an estimated $23.3K.
Citadel Advisors first reported a position in BioNexus Gene Lab in Q3 2023 and held it in 3 quarters.
Citadel Advisors's BioNexus Gene Lab position peaked at $43.5K in Q3 2023.
1 fund tracked by Wall St. Rank held BioNexus Gene Lab as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.